Introduction
The ability of small molecules to distinguish between eukaryotic and prokaryotic protein synthesis has provided the basis of antimicrobial activity for a number of clinically valuable antibiotics 1, 2 . This includes the antibiotic mupirocin, which is used therapeutically as a topical agent targeting the active site of Gram positive isoleucyl-tRNA Ile synthetase (IleRS) [3] [4] [5] , preventing the formation of isoleucyl-tRNA Ile . However, the lack of systemic efficacy of mupirocin and its inactivity against Gram negative and TB infections 6,7 as well as the rise of mupirocin resistance in MRSA and MSSA 3, 8 has increased the need for new inhibitors targeting this class of enzymes.
Many aminoacyl-tRNA synthetases (AaRSs) cannot bind the correct amino acid with sufficient accuracy to ensure the fidelity of protein synthesis 9 . Therefore these enzymes have developed editing strategies to remove incorrectly aminoacylated intermediates and mis-aminoacylated tRNAs in what are termed pre and post-transfer editing mechanisms.
These mechanisms are partitioned between the active site (pre-transfer) and a physically distinct dedicated (post-transfer) editing domain [10] [11] [12] [13] [14] . Recent attempts to target the interaction of tRNA Leu with the post-transfer editing domain of leucyl-tRNA Leu synthetase (LeuRS) from Gram negative pathogens with small molecule boron inhibitors have been abandoned because of the rapid onset of resistance in clinical trials due to mutation 15 . The clinical efficacy of mupirocin compared to that of small molecule boron inhibitors highlights the relative essentiality and mutability of the active site versus the post-transfer editing sites of AaRSs and consequently their value as antibacterial targets particularly where synthetases utilise more than one mechanism of editing (16, 17) . This weakness in targeting post-transfer editing in prokaryotes is further illustrated by Escherichia coli LeuRS where mutation of the post-transfer editing site unveils a pre-transfer-editing capability However, the utilization of radiolabels can be problematic, it precludes continuous monitoring of AaRS activity and because of the costs of purchase and disposal, often precludes high throughput and saturating substrate experiments 19 . This and the success of mupirocin suggest a significant advance in inhibitor screening could be leveraged by introduction of continuous non-radioactive assays that monitored AaRS catalysed aminoacyl adenylate turnover. Furthermore, such an assay could also be applied more generally to AaRS enzymology.
For many synthetases, the nucleophile attacking the aminoacyl-adenylate can also be the oxygen atom appended to the -phosphorous of a second molecule of ATP, instead of pyrophosphate or tRNA, which attacks the -phosphorus of the adenylate moiety of the aminoacyl-adenylate. This results in the amino acid-dependent formation of Ap 4 A ( Figure 1 , reaction 3) [20] [21] [22] [23] .
Reversal of amino acid-dependent Ap 4 A formation by AaRSs, in the presence of pyrophosphate would be expected to generate two molecules of ATP which could then be detected by spectrophotometric, fluorometric or bioluminescent methodologies. This would provide a viable alternative to [ 32 P]-pyrophosphate exchange assays. Therefore, we demonstrate here that amino acid, pyrophosphate and Ap 4 A dependent ATP generation can be followed continuously by tractable spectrophotometric coupled assays that can be applied to the now straightforward characterization of AaRS enzymology and for detection of inhibitors of a number of these essential drug targets.
Results and Discussion
Requirement for the generation of novel AaRS assays. We initially identified the assay partially developed by Roy 24 as a starting point. Here, the pyrophosphate nucleophile attacking the aminoacyl adenylate intermediate would exchange for the imidodiphosphate moiety of 5'-adenylyl--imidodiphosphate (ADPNP) in the presence of the amino acid to generate ATP that could then be assayed spectrophotometrically (Supporting Information Figure 1 ( Figure S1a) ). This approach was flawed by the inability of Roy 24 to show dependence of the rates detected on pyrophosphate. Nevertheless we re-developed this method to obtain a working assay that was applicable to E. coli and Streptococcus pneumoniae alanyl-tRNA Ala and S. pneumoniae seryl-tRNA Ser synthetases (AlaRS and SerRS) that we kinetically characterised (Table S1 and Figure S2a -i).
However we found this approach was limited by the inability of the class I IleRS and valyl-tRNA Val synthetases (ValRS) from E. coli to utilise ADPNP ( Figure S1b ), as was also found for the baker's yeast enzymes by Friest et al. 25 . Furthermore, the low ADPNP K m App of E. coli AlaRS (4.8 ± 0.64 µM; Table S1 ) reduced the sensitivity of the assay to the detection of competitive inhibitors. It is possible that this restriction of adenine nucleotide specificity is related to the differential mode of ATP binding to class I and II synthetases 14, 26 . To enable access to the enzymology of both class I and II AaRSs, in the context of screening for small molecule inhibitors with a high degree of sensitivity to hit detection, we sought another potential adenylate based substrate to support pyrophosphate exchange activity. . We investigated the reverse of this process where the synthetase would catalyse the amino acid and pyrophosphate dependent pyrophosphorolysis of Ap 4 A to form two molecules of ATP that could be continuously monitored ( Figure 2 ).
Reversal of AaRS-catalysed Ap
The assays based around the conversion of Ap 4 A to ATP require a detection system that could distinguish between these phosphonucleotides and provide a read out of ATP in the presence of a considerable excess of Ap 4 A. The ability of hexokinase to discriminate between ATP and ATP analogues such as ADPNP 24 and adenosine  methylene triphosphate (Lloyd, unpublished) was therefore tested with respect to Ap 4 A. Here, phosphorylation of glucose with ATP by hexokinase was coupled to oxidation of the resulting glucose 6-phosphate to 6-phosphogluconate with reduction of NADP + by glucose 6-phosphate dehydrogenase to generate NADPH and therefore a spectrophotometric readout at 340 nm ( Figure 2 ). Under these circumstances, in the presence of 6.33 mM Ap 4 A, no significant change in absorbance could be detected. However, on addition of 0.1 mM ATP, there was an instantaneous increase in absorbance consistent with the concentration of ATP in the assay. This suggested that the coupling system could adequately discriminate between ATP and Ap 4 A and was not significantly inhibited by the dinucleotide.
We then tested the ability of E. coli AlaRS, E. coli ValRS and E. coli IlelRS to catalyse ATP production from Ap 4 A and investigated the dependence of this process on the presence of the synthetase, the cognate amino acid and pyrophosphate. All three enzymes showed linear Ap 4 A, pyrophosphate, synthetase and amino acid dependent production of ATP as an increase in absorbance at 340nm over the rate measured in the absence of any one of these components (Figure 3a -c).
To prove that the assay followed the pyrophosphorolytic cleavage of Ap 4 A we followed a time course of the complete consumption of the diadenosine nucleotide by S.pneumoniae AlaRS in the presence of L-alanine and excess pyrophosphate. We observed that by the end point of the reaction, two equivalents of ATP were produced per equivalent of Ap 4 A (Figure 3d ). This was consistent with the stoichiometry of the cleavage of Ap 4 A by pyrophosphate.
The reaction scheme of amino acid-dependent AaRS catalysed pyrophosphorolysis of Ap 4 A indicated that the reaction would not be limited by the concentration of the amino acid which is regenerated per catalytic cycle ( Figure 2 ). Therefore, we performed assays with IleRS at a limiting (10 M) concentration of L-isoleucine. The absorbance of the assay at 340 nm extended beyond that expected where L-isoleucine was simply consumed (0.062 AU), to that consistent with consumption of the next limiting substrate in the assay (pyrophosphate; Figure 3c ). (Figure 4 and Figure S4 ). Here, the efficiencies reported by relative (Table 1 ). This level of discrimination is similar to that between Lisoleucine and L-valine which has required the evolution of both post and pre-transfer editing domains to eliminate erroneous incorporation of L-valine at L-isoleucine codons [9] [10] [11] [12] [13] [14] 32, 34 .
Characterization of AaRS
Previous attempts 37 to demonstrate D-isoleucine utilization by IleRS were not successful, however, these assays were performed with a limit of detection of >1% the rate with cognate L-isoleucine
37
, and as we have demonstrated here, although significant, the efficiency of the enzyme with D-isoleucine is less than~0.5% of that with L-isoleucine. . None of these inhibitors affected the activity of the hexokinase/glucose 6 phosphate dehydrogenase coupling system.
Interestingly, the overlapping potency of the above aminoacyl adenylate mimetics are consistent with the overlapping amino acid substrate specificity of these three synthetases 9, 11, 13, 33, 40 . Therefore, development of multi-targeted AaRS inhibitors using for example seryl-adenylate analogues as a starting point may allow development of novel antimicrobials which are robust with respect to the evolution of resistance. Under these conditions, the standard deviation of the assays for both enzymes expressed as a percentage of the mean value for a triplicate determination of initial rate was 7.0 % (range, 2.4% -9.2% n = 7) for IleRS and 4.8 % (range, 1.7% -8.1% n = 10) for ValRS.
Assessment of the Ap
Assuming a positive identification of an inhibitor was a drop in measured activity of at least three standard deviations and competitive kinetics, these assays would detect IleRS inhibitors competitive with L-isoleucine, Ap 4 A and pyrophosphate with K i values ≤ 3.0 mM, ≤ 3.4 mM and ≤ 0.51 mM respectively at a set inhibitor concentration of 1 mM. Similarly,
ValRS inhibitors competitive with L-valine, Ap4A and pyrophosphate with K i values ≤ 4.5 mM, ≤ 5.0 mM and ≤ 0.43 mM respectively would be expected to be detected.
We assessed the signal:noise ratio of the assay (the ratio of rates with and without pyrophosphate). For IleRS and ValRS, the signal to noise ratios of the assays at the concentration of the enzyme used in screening (2.25 M and 2.21 M respectively) were 3.86 ± 1.15 (n= 35 positive controls) and 7.79 ± 2.14 (n = 30 positive controls) respectively.
We further characterised the ability of the assay to discriminate between the presence and absence of standard inhibitors. The Z' values 45 for the IleRS assay with respect to inhibition by 5 M mupirocin and the ValRS assay with respect to inhibition by 50
M threonyl-5'-sulphamoyl adenosine were 0.84 and 0.792, suggesting excellent discrimination between positive and negative control assays.
With the assay thus configured, we screened a library of 73 compounds against both enzymes. Although we were unable to identify novel dual targeted inhibitors in this manner, . These dyes were Procion Red HE-3B, Procion Green HE4BD and Trypan Blue. IC 50 values for these compounds were 2.14 ± 0.29 M, 6.98 ± 1.23 M and 19.2 ± 8.6 M respectively (Figures 7a-c) .
Interestingly, Procion Green HE4BD inhibits Bacillus stearothermophilus methionyl- Table 1 . Data were fitted to the Michaelis Menten equation using GraphPad Prizm yielding the kinetic constants shown in Table 1 . When held constant, the concentrations of pyrophosphate, ADPNP and L-amino acid were as reported in Table S1 . [SerRS] was at 2.08 M. Assays were initiated by the addition of L-serine and performed at 
